RxDoctor Payments Data

Bichngoc Pham, MD

Family Medicine · Tampa, FLNPI 1033283965

Payments from drug & device makers

$1,930in general payments, 2019–2025

Across 54 payments — averaging $35.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$941
  • Novo Nordisk$226
  • Gilead$147
  • Merz North America, Inc.$131
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$83
  • Boehringer Ingelheim$46
  • plus $356 from 14 others

What the payments were for

  • Food & beverage$1,90299%
  • Gifts$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,930 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$9,060
Medicare patients
26
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin16$20,466
MounjaroTirzepatide12$19,271
OzempicSemaglutide12$18,337
EliquisApixaban18$13,467
Atorvastatin Calcium98$935
Fluticasone Propionate30$659
Olmesartan Medoxomil21$473
Omeprazole26$469
Levothyroxine Sodium40$314
Albuterol Sulfate HfaAlbuterol Sulfate13$274
Tamsulosin Hcl11$273
Duloxetine Hcl14$233
Lisinopril35$216
Hydrochlorothiazide22$207
Metformin Hcl34$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$46$20,46616 claims
Lilly USA, LLCMounjaro$16$19,27112 claims
Novo NordiskOzempic$226$18,33712 claims
PfizerEliquis$42$13,46718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →